Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome

Clinical and Experimental Rheumatology

Wolfgang L. Gross¹  Frank Moosig¹  Kristine Herrmann¹ 

关键词: Churg-Strauss syndrome;    mepolizumab;    IL-5;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: To report on the extended follow-up of relapsing/refractory CSS patients treated with mepolizumab with respect to relapse rates. METHODS: The follow-up consisted of regular clinic visits of patients who received nine infusions of mepolizumab (750mg IV) and switched to methotrexate 0.3mg/kg for maintenance of remission. Glucocorticoids were maintained as low as possible. Disease activity was measured using the Birmingham Vasculitis Activity Score (BVAS). Disease states as remission or relapse were defined according to the EULAR/EUVAS recommendations. The serum eosinophil cationic protein (ECP) was measured regularly and concentrations were correlated with BVAS. RESULTS: The follow-up of the study population under standard methotrexate maintenance therapy was extended to a median of 22 months. Three of nine patients were still in remission at the end of follow-up. During this time five major relapses in three and seven minor relapses in five out of the total nine patients were recognised. ECP levels were found to correlate stronger with the BVAS (r=0.38; p

【 授权许可】

Unknown